At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Apr 22, 2026 at 16:09 ET
Stoke Therapeutics' 2026 proxy statement details the election of three Class I directors, ratification of auditors, and advisory approval of executive compensation. This filing is routine governance material, routine for a biotech company.
- Election of Class I directors: G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D., and Julie Anne Smith
- Ratification of Ernst & Young LLP as independent auditors for fiscal year 2026
- Advisory vote on executive compensation
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access